Omalizumab to increase tolerance to common food allergens in people with high total IgE

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 trial enrolls people aged 1–55 with IgE‑mediated allergy to foods such as peanut, tree nuts, egg, milk, or wheat who have total IgE levels above current FDA-based dosing tables. Participants receive omalizumab injections every two weeks for 24 weeks; those who demonstrate increased tolerance may then undergo an 8-week twice-weekly injection period while reintroducing the food into the diet. Key entry requirements include a skin prick test wheal ≥6 mm, food-specific IgE ≥2.0 kUA/L, and a positive double-blind, placebo-controlled food challenge with a low cumulative threshold (≤144 mg; max tolerated ≤30 mg). The trial is led by Johns Hopkins with Genentech collaboration and is conducted at the Johns Hopkins site in Baltimore, Maryland.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 1 to 55 years
* A positive prick skin test (PST) with a wheal ≥ 6 mm to at least one of the relevant foods (peanut, cashew, walnut, egg, milk, or wheat)
* Positive food-specific IgE (≥2.0 kilo units of allergen-specific IgE per liter (kUA/L)) to at least one of the study specific foods
* A weight / IgE level that would have excluded the participant from the OUTMATCH study based on the dosing table noted above
* Positive double-blind, placebo-controlled food challenge (DBPCFC) to one of the relevant foods at a cumulative dose of ≤144 mg (maximum tolerated dose ≤30 mg)

Exclusion Criteria:

* Clinically significant laboratory abnormalities at screening.
* Dose-limiting symptoms during the blinded food challenge to placebo during the screening DBPCFC.
* Poorly controlled or severe asthma/wheezing at screening
* History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise or requiring intubation.
* Treatment with a burst of oral, intramuscular (IM), or intravenous (IV) steroids of more than two days for an indication other than asthma/wheezing within 30 days of screening.
* Currently receiving oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers.
* Past or current history of eosinophilic gastrointestinal disease within three years of screening.
* Past or current history of cancer, or currently being investigated for possible cancer.
* Past or current history of any food immunotherapy (e.g., oral immunotherapy (OIT), sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT) within 6 months of screening.
* Treatment with monoclonal antibody therapy, such as omalizumab, dupilumab, benralizumab, mepolizumab, reslizumab, tezepelumab, or other immunomodulatory therapy within 6 months of screening.
* Inability to discontinue antihistamines for minimum wash-out periods required for skin prick tests (SPTs) or oral food challenges (OFCs).
* Pregnant or breastfeeding, or intending to become pregnant during the study
* Evidence of clinically significant chronic disease.

Where it's running

• Johns Hopkins
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Robert Wood, MD — Johns Hopkins University
• Study coordinator: Robert Wood, MD
• Email: rwood@jhmi.edu
• Phone: 410-955-5883

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral Food Challenge After Starting Omalizumab in Food Allergy

  This trial tests whether omalizumab begins to help with food allergy within 2 to 4 weeks after starting treatment in people with a confirmed food allergy.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07845552

• Severe chronic urticaria not responding to high-dose omalizumab in France

  This study looks at adults with chronic spontaneous or inducible urticaria who don’t respond to optimized omalizumab to see what factors are linked to non-response and what other options people use.

  Recruiting Centre Hospitalier Universitaire de Besancon · Besançon, Franche-comté · NCT07833696

• Remibrutinib and omalizumab-based treatment approach for adults with chronic spontaneous urticaria not well controlled by antihistamines

  This trial tests a sequencing plan using remibrutinib and omalizumab to see if it helps adults with chronic spontaneous urticaria that isn’t well controlled by second-generation antihistamines.

  Recruiting at 10 sites Phase 3 Novartis · London, Ontario and 9 other locations · NCT07816328

• Can specific IgE to shrimp proteins help diagnose shrimp allergy in children

  This study tests whether blood tests for IgE antibodies to tropomyosin and hemocyanin can improve diagnosing shrimp allergy in children who may be allergic.

  Recruiting University of Medicine and Pharmacy at Ho Chi Minh City · Ho Chi Minh City · NCT07501325

• Switching to Omlyclo® (omalizumab biosimilar) for adults with chronic spontaneous urticaria or severe allergic asthma

  This will try switching adults who are stable on reference omalizumab to the biosimilar Omlyclo® to see if disease control and patient satisfaction stay the same over 12 months.

  Recruiting Celltrion HealthCare France · Montpellier · NCT07425639

• Extensively hydrolysed whey formula with synbiotics and 2'-FL for infants with cow's milk protein allergy

  This study tests whether an extensively hydrolysed whey-based infant formula with synbiotics and the human milk sugar 2'-fucosyllactose (2'-FL) helps infants under 10 months who have suspected or confirmed cow's milk protein allergy.

  Recruiting at 13 sites Outcomes'10 · Valencia, Valencia and 12 other locations · NCT07342621

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.